

William E Evans

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6861454/william-e-evans-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

456
papers

45,450
citations

108
h-index

206
g-index

487
ext. papers

50,850
ext. citations

8.6
avg, IF

7.2
L-index

#	Paper	IF	Citations
456	Pharmacogenomics: translating functional genomics into rational therapeutics. <i>Science</i> , 1999 , 286, 487-91	33.3	1986
455	Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. <i>Cancer Cell</i> , 2002 , 1, 133-43	24.3	1541
454	Treatment of acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 2006 , 354, 166-78	59.2	1493
453	Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. <i>Nature</i> , 2007 , 446, 758-64	50.4	1398
452	Pharmacogenomics--drug disposition, drug targets, and side effects. <i>New England Journal of Medicine</i> , 2003 , 348, 538-49	59.2	1383
451	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012 , 481, 157-63	50.4	1163
450	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 1005-15	59.2	885
449	Treating childhood acute lymphoblastic leukemia without cranial irradiation. <i>New England Journal of Medicine</i> , 2009 , 360, 2730-41	59.2	868
448	Acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 1998 , 339, 605-15	59.2	743
447	A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. <i>Lancet Oncology</i> , 2009 , 10, 125-34	21.7	665
446	Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 1991 , 325, 1682-7	59.2	599
445	Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 2001-8	9.7	589
444	Moving towards individualized medicine with pharmacogenomics. <i>Nature</i> , 2004 , 429, 464-8	50.4	583
443	Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. <i>Annals of Internal Medicine</i> , 1997 , 126, 608-14	8	566
442	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2012 , 22, 153-66	24.3	515
441	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2938-48	2.2	509
440	Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. <i>New England Journal of Medicine</i> , 2004 , 351, 533-42	59.2	492

439	Pharmacogenomics and individualized drug therapy. <i>Annual Review of Medicine</i> , 2006 , 57, 119-37	17.4	486
438	Pharmacogenomics in the clinic. <i>Nature</i> , 2015 , 526, 343-50	50.4	455
437	Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 387-91	6.1	433
436	Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 1998 , 338, 499-505	59.2	396
435	Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. <i>Blood</i> , 2012 , 120, 1165-74	2.2	383
434	Germline genomic variants associated with childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2009 , 41, 1001-5	36.3	383
433	Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2000 , 14, 567-72	10.7	380
432	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIII B at St Jude Children's Research Hospital. <i>Blood</i> , 2004 , 104, 2690-6	2.2	366
431	Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. <i>Journal of Pediatrics</i> , 1991 , 119, 985-9	3.6	365
430	Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 2003 , 349, 640-9	59.2	355
429	Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2293-301	2.2	351
428	High incidence of secondary brain tumours after radiotherapy and antimetabolites. <i>Lancet, The</i> , 1999 , 354, 34-9	40	341
427	Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. <i>New England Journal of Medicine</i> , 1986 , 314, 471-7	59.2	313
426	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. <i>Blood</i> , 1999 , 93, 2817-2823	2.2	306
425	Pharmacogenomics: the inherited basis for interindividual differences in drug response. <i>Annual Review of Genomics and Human Genetics</i> , 2001 , 2, 9-39	9.7	302
424	Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. <i>Annual Review of Pharmacology and Toxicology</i> , 2015 , 55, 89-106	17.9	292
423	Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. <i>Lancet, The</i> , 1991 , 337, 61-6	40	292
422	A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 949-53	11.5	291

421	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. <i>Nature Genetics</i> , 2016 , 48, 367-73	36.3	285
420	Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1235-42	2.2	278
419	Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5972-8	2.2	269
418	Pharmacogenomics: unlocking the human genome for better drug therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2001 , 41, 101-21	17.9	267
417	Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 93, 324-5	6.1	263
416	Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 52, 643-58	6.1	262
415	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1095-1105	6.1	247
414	Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. <i>Science</i> , 1995 , 267, 886-91	33.3	241
413	The Pediatric Cancer Genome Project. <i>Nature Genetics</i> , 2012 , 44, 619-22	36.3	239
412	Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 6444-9	11.5	234
411	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1997 , 89, 1701-1707	2.2	233
410	Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1207-15	27.4	226
409	Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 279-90		226
408	Thiopurine methyltransferase activity in American white subjects and black subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 15-20	6.1	226
407	Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. <i>Nature Genetics</i> , 2003 , 34, 85-90	36.3	220
406	Childhood acute lymphoblastic leukaemia--current status and future perspectives. <i>Lancet Oncology</i> , 2001 , 2, 597-607	21.7	217
405	Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013 , 45, 290-4	36.3	216
404	Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2010 , 24, 371-82	10.7	216

403	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013 , 45, 1494-8	36.3	205
402	Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. <i>Blood</i> , 2013 , 122, 2622-9	2.2	205
401	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2011 , 43, 237-41	36.3	201
400	Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. <i>Human Molecular Genetics</i> , 1999 , 8, 371-6	5.6	196
399	A 50-year journey to cure childhood acute lymphoblastic leukemia. <i>Seminars in Hematology</i> , 2013 , 50, 185-96	4	195
398	Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2014 , 32, 949-59	2.2	190
397	Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3012-20	2.2	190
396	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019 , 51, 296-307	36.3	189
395	Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2011 , 117, 2340-7; quiz 2556	2.2	185
394	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. <i>Blood</i> , 2005 , 105, 4752-8	2.2	182
393	Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. <i>Nature Reviews Cancer</i> , 2006 , 6, 117-29	31.3	180
392	Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 815-23	27.4	179
391	Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. <i>Genome Research</i> , 2012 , 22, 1-8	9.7	177
390	TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. <i>Journal of Clinical Oncology</i> , 1997 , 15, 1150-7	2.2	176
389	Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. <i>Leukemia</i> , 2003 , 17, 700-6	10.7	176
388	Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. <i>Leukemia</i> , 2000 , 14, 2286-94	10.7	175
387	Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 393-403	27.4	174
386	Late effects of treatment in survivors of childhood acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3273-9	2.2	170

385	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998 , 92, 411-415	2.2	170
384	PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014 , 166C, 45-55	3.1	169
383	Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 164-72	6.1	168
382	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 733-42	9.7	167
381	Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. <i>Leukemia</i> , 1998 , 12, 346-52	10.7	166
380	Ancestry and pharmacogenetics of antileukemic drug toxicity. <i>Blood</i> , 2007 , 109, 4151-7	2.2	166
379	Multiplex assessment of protein variant abundance by massively parallel sequencing. <i>Nature Genetics</i> , 2018 , 50, 874-882	36.3	163
378	Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. <i>Blood</i> , 2009 , 113, 2014-21	2.2	162
377	Patient characteristics associated with high-risk methotrexate concentrations and toxicity. <i>Journal of Clinical Oncology</i> , 1994 , 12, 1667-72	2.2	161
376	Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 186-91	3.2	160
375	Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. <i>Lancet, The</i> , 2000 , 356, 285-90	4.0	159
374	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2008 , 112, 4178-83	2.2	157
373	Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. <i>Journal of Clinical Investigation</i> , 1996 , 97, 73-80	15.9	153
372	Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 1994 , 94, 1996-2001	15.9	150
371	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2000 , 96, 3381-3384	2.2	149
370	Development and use of active clinical decision support for preemptive pharmacogenomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014 , 21, e93-9	8.6	148
369	Pharmacogenomics and individualized medicine: translating science into practice. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 467-75	6.1	148
368	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016 , 48, 1481-1489	36.3	145

367	Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2005 , 7, 375-86	24.3	139
366	Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 1997 , 336, 1781-7	59.2	138
365	Genome-wide study of methotrexate clearance replicates SLCO1B1. <i>Blood</i> , 2013 , 121, 898-904	2.2	137
364	Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. <i>Leukemia</i> , 1997 , 11, 1813-6	10.7	134
363	Ligation of CD38 suppresses human B lymphopoiesis. <i>Journal of Experimental Medicine</i> , 1995 , 181, 1101-106	10.6	132
362	ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 751-7	2.2	131
361	Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1525-32	2.2	131
360	Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. <i>Pharmacology</i> , 2000 , 61, 136-46	2.3	130
359	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 207-10	6.1	128
358	Pharmacogenetics of cancer therapy: getting personal. <i>American Journal of Human Genetics</i> , 1998 , 63, 11-6	11	126
357	Results of therapy for acute lymphoblastic leukemia in black and white children. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 2001-7	27.4	126
356	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. <i>Lancet Oncology, The</i> , 2015 , 16, 1659-66	21.7	123
355	6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood</i> , 2014 , 124, 2345-53	2.2	123
354	Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. <i>Blood</i> , 2003 , 101, 3862-7	2.2	122
353	The genomic landscape of childhood and adolescent melanoma. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 816-823	4.3	121
352	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. <i>Lancet Oncology, The</i> , 2015 , 16, 465-74	21.7	118
351	Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. <i>Cancer Research</i> , 2008 , 68, 4983-9	10.1	117
350	Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2370-6	2.2	115

349	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. <i>Journal of Clinical Investigation</i> , 2005 , 115, 110-7	15.9	108
348	The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2006 , 107, 769-76	2.2	107
347	Thiopurine methyltransferase in acute lymphoblastic leukemia. <i>Blood</i> , 2006 , 107, 843-4	2.2	107
346	Drug methylation in cancer therapy: lessons from the TPMT polymorphism. <i>Oncogene</i> , 2003 , 22, 7403-13	2.2	107
345	Sex differences in prognosis for children with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1999 , 17, 818-24	2.2	103
344	Improved prognosis for older adolescents with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 386-91	2.2	102
343	Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. <i>Journal of Pediatrics</i> , 1994 , 125, 642-9	3.6	102
342	Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. <i>Leukemia</i> , 2009 , 23, 1406-9	10.7	100
341	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018 , 33, 937-948.e8	24.3	98
340	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. <i>Blood</i> , 1999 , 93, 1643-1650	2.2	98
339	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. <i>Nature Genetics</i> , 2015 , 47, 607-14	36.3	96
338	Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. <i>Nature Medicine</i> , 2011 , 17, 1298-303	50.5	95
337	Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. <i>Cancer</i> , 1981 , 48, 1715-8	6.4	95
336	Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. <i>Clinical Pharmacokinetics</i> , 1989 , 16, 327-36	6.2	94
335	PharmGKB summary: methotrexate pathway. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 679-86	1.9	93
334	Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. <i>Journal of Clinical Oncology</i> , 1987 , 5, 1007-14	2.2	93
333	Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. <i>Cancer</i> , 1982 , 49, 1378-83	6.4	93
332	Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 308-13	6.1	92

331	Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. <i>Human Molecular Genetics</i> , 1994 , 3, 923-6	5.6	91
330	Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. <i>Leukemia</i> , 2017 , 31, 333-339	10.7	90
329	Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. <i>Pharmaceutical Research</i> , 1999 , 16, 342-9	4.5	90
328	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. <i>Blood</i> , 2012 , 120, 4197-204	2.2	89
327	Differences in folypolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylolation and cytotoxicity. <i>Molecular Pharmacology</i> , 1997 , 52, 155-63	4.3	89
326	Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1979 , 3, 161-6	3.5	89
325	Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2005-12 ^{2.2}	2.2	87
324	A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 563-6	6.1	87
323	Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1982 , 7, 147-50	3.5	87
322	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2015 , 126, 1770-6	2.2	86
321	Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. <i>Journal of Pediatrics</i> , 1987 , 111, 606-12	3.6	85
320	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018 , 36, 591-599	2.2	85
319	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015 , 125, 680-6	2.2	84
318	Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>JAMA Oncology</i> , 2015 , 1, 287-95	13.4	84
317	Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. <i>Leukemia</i> , 2012 , 26, 2303-9	10.7	83
316	A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. <i>Cancer Research</i> , 2003 , 63, 100-6	10.1	83
315	Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. <i>Lancet Oncology</i> , 2010 , 11, 507-9	21.7	82
314	Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2959-64	2.2	82

313	Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1998 , 16, 3768-73	2.2	82
312	Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 568-73	6.1	82
311	ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. <i>Leukemia</i> , 2012 , 26, 265-70	10.7	80
310	De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. <i>Blood</i> , 2002 , 100, 1240-7	2.2	80
309	Nomenclature for alleles of the thiopurine methyltransferase gene. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 242-8	1.9	79
308	Structure and dynamics of thioguanine-modified duplex DNA. <i>Journal of Biological Chemistry</i> , 2003 , 278, 1005-11	5.4	79
307	Relation of systemic exposure to unbound etoposide and hematologic toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 385-93	6.1	79
306	Epigenetic Regulation of Human β -Glutamyl Hydrolase Activity in Acute Lymphoblastic Leukemia Cells. <i>American Journal of Human Genetics</i> , 2010 , 87, 161	11	78
305	Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 641-50	1.9	77
304	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3377-3391	2.2	75
303	Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. <i>Journal of Clinical Oncology</i> , 1991 , 9, 1022-8	2.2	75
302	Etoposide pharmacokinetics in patients with normal and abnormal organ function. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1690-5	2.2	75
301	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2005 , 103, 368-76	6.4	73
300	Thiopurine pathway. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 573-4	1.9	71
299	Altered protein binding of etoposide in patients with cancer. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 49-55	6.1	71
298	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. <i>Blood</i> , 2014 , 124, 1266-76	2.2	70
297	ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. <i>Leukemia</i> , 2010 , 24, 894-6	10.7	70
296	Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 93-9		70

295	Effect of pleural effusion on high-dose methotrexate kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 1978 , 23, 68-72	6.1	70
294	A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 557-67		69
293	Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. <i>Blood</i> , 2012 , 119, 1658-64	2.2	67
292	Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 46-51	6.1	67
291	A novel CRM1-mediated nuclear export signal governs nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase following genotoxic stress. <i>Journal of Biological Chemistry</i> , 2004 , 279, 5984-92	5.4	67
290	Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. <i>Pharmacogenetics and Genomics</i> , 1995 , 5, 281-6		67
289	Increased teniposide clearance with concomitant anticonvulsant therapy. <i>Journal of Clinical Oncology</i> , 1992 , 10, 311-5	2.2	67
288	Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 301-7	6.1	67
287	Novel variants in and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. <i>Blood</i> , 2017 , 130, 1209-1212	2.2	65
286	Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7936-41	2.2	64
285	Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. <i>Journal of Clinical Oncology</i> , 1990 , 8, 1874-9	2.2	64
284	Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. <i>Journal of Clinical Investigation</i> , 1993 , 91, 2150-4	15.9	64
283	Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. <i>Nature Genetics</i> , 2005 , 37, 878-82	36.3	63
282	Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. <i>Cancer</i> , 1988 , 62, 884-8	6.4	63
281	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. <i>Blood</i> , 2015 , 126, 2896-9	2.2	62
280	BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. <i>Haematologica</i> , 2015 , 100, e354-7	6.6	61
279	Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 88, 191-6	6.1	61
278	In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. <i>PLoS Medicine</i> , 2008 , 5, e83	11.6	60

277	Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2005 , 105, 4223-5	2.2	60
276	Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1504-11	2.2	57
275	Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1996 , 14, 399-404	2.2	57
274	Methotrexate bioavailability after oral and intramuscular administration in children. <i>Journal of Pediatrics</i> , 1987 , 110, 788-92	3.6	57
273	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2133-40	2.2	57
272	High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. <i>Annals of Neurology</i> , 1994 , 36, 920-4	9.4	55
271	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015 , 126, 69-75	2.2	54
270	Pharmacokinetics of anticancer drugs in children. <i>Clinical Pharmacokinetics</i> , 1987 , 12, 168-213	6.2	54
269	Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 1990 , 47, 540-6	6.1	52
268	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. <i>Nature Communications</i> , 2015 , 6, 7553	17.4	51
267	Aspirin alters methotrexate disposition in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 1991 , 34, 1514-20		51
266	Second malignancy after treatment of childhood non-Hodgkin lymphoma. <i>Cancer</i> , 2001 , 92, 1959-66	6.4	51
265	Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. <i>Journal of Pediatrics</i> , 1993 , 123, 471-9	3.6	51
264	The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1792-803	9.7	50
263	A novel protein complex distinct from mismatch repair binds thioguanylated DNA. <i>Molecular Pharmacology</i> , 2001 , 59, 367-74	4.3	50
262	Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 23-37	4.1	48
261	Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. <i>Trends in Molecular Medicine</i> , 2002 , 8, 300-5	11.5	48
260	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. <i>Human Molecular Genetics</i> , 2012 , 21, 4793-804	5.6	47

259	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2051-2061	2.2	46
258	Pharmacogenetics in acute lymphoblastic leukemia. <i>Seminars in Hematology</i> , 2009 , 46, 39-51	4	46
257	Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. <i>Blood</i> , 2005 , 106, 1778-85	2.2	46
256	High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. <i>Journal of Pharmaceutical Sciences</i> , 1984 , 73, 164-8	3.9	46
255	A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. <i>Leukemia</i> , 2011 , 25, 66-74	10.7	45
254	Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. <i>Blood</i> , 2009 , 113, 4512-20	2.2	45
253	Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. <i>Blood Cancer Discovery</i> , 2020 , 1, 96-111	7	44
252	Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. <i>Journal of Biological Chemistry</i> , 2014 , 289, 20502-15	5.4	44
251	MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression. <i>PLoS Computational Biology</i> , 2016 , 12, e1004744	5	44
250	Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies. <i>Cancer</i> , 1990 , 65, 439-45	6.4	43
249	High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X. <i>Medical and Pediatric Oncology</i> , 1988 , 16, 297-303		43
248	HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy. <i>Clinical Chemistry</i> , 2002 , 48, 61-68	5.5	42
247	Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 132-40	6.1	42
246	Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. <i>Pharmacogenomics</i> , 2014 , 15, 1065-78	2.6	41
245	An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 101, 391-395	6.1	39
244	Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. <i>Blood</i> , 2002 , 100, 43-7	2.2	39
243	Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1771-8	2.2	38
242	Enhanced hepatic drug clearance in patients with cystic fibrosis. <i>Journal of Pediatrics</i> , 1990 , 117, 972-9	3.6	38

241	The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. <i>Journal of Clinical Oncology</i> , 1984 , 2, 655-61	2.2	38
240	Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2002 , 15, 741-56	4.2	37
239	Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. <i>Pharmaceutical Research</i> , 1997 , 14, 1672-8	4.5	36
238	Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. <i>PLoS Computational Biology</i> , 2010 , 6, e1001019	5	35
237	Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. <i>Human Molecular Genetics</i> , 2007 , 16, 2261-71	5.6	35
236	Childhood acute lymphoblastic leukemia. <i>Reviews in Clinical and Experimental Hematology</i> , 2002 , 6, 161-80; discussion 200-2		35
235	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 419-28	3.5	35
234	Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. <i>Blood</i> , 2004 , 104, 1435-41	2.2	35
233	Unravelling the functional genomics of the human CYP2D6 gene locus. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 553-4		34
232	Simultaneous administration of multiple model substrates to assess hepatic drug clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 645-50	6.1	34
231	Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 651-60	6.1	34
230	Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. <i>Blut</i> , 1988 , 56, 241-8		34
229	A model for dosing gentamicin in children and adolescents that adjusts for tissue accumulation with continuous dosing. <i>Clinical Pharmacokinetics</i> , 1980 , 5, 295-306	6.2	34
228	Cisplatin disposition in children and adolescents with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1981 , 6, 95-9	3.5	33
227	Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. <i>Clinical Cancer Research</i> , 2002 , 8, 2423-9	12.9	33
226	Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. <i>Cancer Research</i> , 2007 , 67, 4965-72	10.1	32
225	Lead poisoning from ingestion of Chinese herbal medicine. <i>Clinical Toxicology</i> , 1977 , 10, 273-81		32
224	Cancer pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 461-6	6.1	31

223	Pharmacogenomics in cancer therapy: is host genome variability important?. <i>Trends in Pharmacological Sciences</i> , 2004 , 25, 457-64	13.2	30
222	Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics. <i>Medical and Pediatric Oncology</i> , 1996 , 26, 85-9		30
221	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. <i>Blood</i> , 1999 , 93, 2817-2823	2.2	30
220	Pharmacogenomics: marshalling the human genome to individualise drug therapy. <i>Gut</i> , 2003 , 52 Suppl 2, ii10-8	19.2	29
219	Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 641-650		29
218	Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1985 , 3, 201-6	2.2	29
217	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. <i>Nature Communications</i> , 2019 , 10, 5348	17.4	29
216	Novel susceptibility variants at the locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019 , 133, 724-729	2.2	29
215	Pharmacogenomics of acute leukemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2006 , 46, 317-53	17.9	28
214	Rapid genotyping of common deficient thiopurine S-methyltransferase alleles using the DNA-microchip technique. <i>European Journal of Human Genetics</i> , 2006 , 14, 991-8	5.3	28
213	Clinical pharmacology of cancer chemotherapy in children. <i>Pediatric Clinics of North America</i> , 1989 , 36, 1199-230	3.6	28
212	Lymphoid gene expression as a predictor of risk of secondary brain tumors. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 107-16	5	27
211	Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. <i>Medical and Pediatric Oncology</i> , 1991 , 19, 153-9		27
210	Lorazepam pharmacodynamics and pharmacokinetics in children. <i>Journal of Pediatrics</i> , 1989 , 114, 641-6	3.6	27
209	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 369-78	3.5	26
208	Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. <i>FEBS Journal</i> , 1998 , 256, 510-7		26
207	Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. <i>American Journal of Human Genetics</i> , 2006 , 79, 264-74	11	26
206	Acute lymphoblastic leukemia in infants. <i>Journal of Clinical Oncology</i> , 1999 , 17, 438-40	2.2	26

205	Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. <i>Journal of Clinical Oncology</i> , 1991 , 9, 1341-7	2.2	26
204	Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. <i>Journal of Pharmaceutical Sciences</i> , 1995 , 84, 824-8	3.9	25
203	Hepatic drug clearance in children: studies with indocyanine green as a model substrate. <i>Journal of Pharmaceutical Sciences</i> , 1989 , 78, 452-6	3.9	25
202	Pharmacogenomics in pediatric leukemia. <i>Current Opinion in Pediatrics</i> , 2010 , 22, 703-10	3.2	24
201	Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 421-3		24
200	Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. <i>Journal of Clinical Oncology</i> , 1993 , 11, 287-93	2.2	24
199	Use of gentamicin serum levels to individualize therapy in children. <i>Journal of Pediatrics</i> , 1978 , 93, 133-7	3.6	24
198	Quantitation of daunorubicin and its metabolites by high-performance liquid chromatography with electrochemical detection. <i>Biomedical Applications</i> , 1982 , 232, 377-83		23
197	Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides. <i>Pharmacotherapy</i> , 1981 , 1, 55-75	5.8	22
196	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28040	3	22
195	Peripheral neuropathy in children and adolescents treated for cancer. <i>The Lancet Child and Adolescent Health</i> , 2018 , 2, 744-754	14.5	22
194	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. <i>Blood</i> , 2017 , 129, 1919-1926	2.2	21
193	Pharmacogenomics of acute lymphoblastic leukemia. <i>Current Opinion in Hematology</i> , 2006 , 13, 260-5	3.3	21
192	Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 181-2		21
191	Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia. <i>Drug Intelligence & Clinical Pharmacy</i> , 1982 , 16, 839-42		21
190	TPMT genetic variations in populations of the Russian Federation. <i>Pediatric Blood and Cancer</i> , 2009 , 52, 203-8	3	20
189	Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. <i>Leukemia Research</i> , 1994 , 18, 811-4	2.7	20
188	High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides. <i>Biomedical Applications</i> , 1983 , 274, 87-93		20

187	Pharmacokinetics of anticancer drugs in children. <i>Drug Metabolism Reviews</i> , 1983 , 14, 847-86	7	20
186	Clinical pharmacology of bleomycin and cisplatin. <i>Head & Neck</i> , 1981 , 4, 98-110		20
185	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1350-1357	9.7	19
184	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020 , 1, 329-344	15.4	19
183	Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. <i>Blood</i> , 2006 , 108, 1984-90 ^{2.2}		19
182	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2021 , 2, 284-299	15.4	19
181	The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. <i>Haematologica</i> , 2013 , 98, 1905-11	6.6	18
180	Loop-column extraction and liquid chromatographic analysis of doxorubicin and three metabolites in plasma. <i>Therapeutic Drug Monitoring</i> , 1985 , 7, 455-60	3.2	18
179	High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethotrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. <i>Biomedical Applications</i> , 1982 , 231, 103-10		18
178	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1730-1736	2.2	17
177	Bleomycin disposition in children with cancer. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 668-73	6.1	17
176	Hepatic drug clearance in patients with mild cystic fibrosis. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 529-40	6.1	16
175	Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells. <i>BMC Cancer</i> , 2019 , 19, 253	4.8	15
174	A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 224-9	6.1	15
173	A simple preparation of the methotrexate metabolites 7-hydroxymethotrexate and 4-deoxy-4-amino-N10-methylpteroic acid. <i>Therapeutic Drug Monitoring</i> , 1983 , 5, 363-6	3.2	15
172	Pharmacokinetics of sustained serum methotrexate concentrations secondary to gastrointestinal obstruction. <i>Journal of Pharmaceutical Sciences</i> , 1981 , 70, 1194-8	3.9	15
171	Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 506-16	6.1	14
170	Global gene expression as a function of germline genetic variation. <i>Human Molecular Genetics</i> , 2005 , 14, 1621-9	5.6	14

169	Gentamicin dosage in children: a randomized prospective comparison of body weight and body surface area as dose determinants. <i>Journal of Pediatrics</i> , 1979 , 94, 139-43	3.6	14
168	Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. <i>SLAS Discovery</i> , 2018 , 23, 164-173	3.4	14
167	Accuracy of Using Pre- and Postdose Gentamicin Serum Concentrations to Estimate Pharmacokinetic Parameters and Adjust Doses in Children and Adolescents. <i>Therapeutic Drug Monitoring</i> , 1981 , 3, 57-62	3.2	14
166	HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. <i>Clinical Chemistry</i> , 2002 , 48, 61-8	5.5	14
165	ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 23-54	2.2	13
164	Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?. <i>Leukemia Research</i> , 1997 , 21, 435-7	2.7	13
163	Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2004 , 43, 103-4	3	13
162	Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. <i>FASEB Journal</i> , 2001 , 15, 1902-8	0.9	13
161	Effect of hepatic irradiation on the toxicity and pharmacokinetics of adriamycin in children. <i>International Journal of Radiation Oncology Biology Physics</i> , 1981 , 7, 953-6	4	13
160	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2000 , 96, 3381-3384	2.2	13
159	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2015 , 10, e0135134	3.7	13
158	The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 176-180	6.1	13
157	Effect of premedications in a murine model of asparaginase hypersensitivity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 541-51	4.7	12
156	Simultaneous analysis of antipyrine and lorazepam by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1986 , 382, 199-205		12
155	Enhancer Hijacking Drives Oncogenic Expression in Lineage-Ambiguous Stem Cell Leukemia. <i>Cancer Discovery</i> , 2021 , 11, 2846-2867	24.4	12
154	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy: Progress Continues. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 315-317	6.1	12
153	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 294-302	1.9	11
152	Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. <i>International Journal of Data Mining and Bioinformatics</i> , 2011 , 5, 143-57	0.5	11

151	Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 39, 592-7	6.1	11
150	High-performance liquid chromatographic assay of mitomycin in biological fluids. <i>Biomedical Applications</i> , 1985 , 345, 197-202		11
149	Phenobarbital-Induced Hepatic Dysfunction. <i>Drug Intelligence & Clinical Pharmacy</i> , 1976 , 10, 439-443		11
148	Comprehensive assessment of thiopurine S-methyltransferase (TPMT) alleles in three ethnic populations. <i>Journal of Pediatric Hematology/Oncology</i> , 2002 , 24, 335-6	1.2	11
147	Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2 ^{-/-} mice. <i>Molecular Pharmacology</i> , 2003 , 64, 456-65	4.3	10
146	Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. <i>Leukemia and Lymphoma</i> , 1995 , 18, 93-102	1.9	10
145	Alternative approaches for Phase I studies of anticancer drugs: a role for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , 1993 , 15, 492-7	3.2	10
144	A longitudinal study of granulocyte colony-stimulating factor levels and neutrophil counts in newborn infants. <i>Journal of Pediatric Hematology/Oncology</i> , 1995 , 17, 176-9	1.2	10
143	Factors affecting in vitro protein binding of etoposide in humans. <i>Journal of Pharmaceutical Sciences</i> , 1992 , 81, 259-64	3.9	10
142	Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2020 , 26, 256-264	12.9	10
141	In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate. <i>Leukemia and Lymphoma</i> , 1998 , 30, 389-94	1.9	9
140	Clinical pharmacology of bleomycin and cisplatin. <i>Drug Intelligence & Clinical Pharmacy</i> , 1982 , 16, 448-58		9
139	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 263-71	1.9	8
138	Molecular cloning and functional characterization of the cDNA encoding the murine thiopurine S-methyltransferase (TPMT). <i>FEBS Letters</i> , 1998 , 424, 143-5	3.8	8
137	Cancer pharmacogenomics may require both qualitative and quantitative approaches. <i>Cell Cycle</i> , 2005 , 4, 1506-9	4.7	8
136	Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2431-2	1.9	8
135	The clinical pharmacist and research. <i>Journal of Clinical Pharmacology</i> , 1981 , 21, 241-4	2.9	8
134	Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 287-293	3.5	7

133	Closing the gap between science and clinical practice: the thiopurine S-methyltransferase polymorphism moves forward. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 395-6		7
132	Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 408-417	9.7	7
131	Genetic abnormalities and drug resistance in acute lymphoblastic leukemia. <i>Advances in Experimental Medicine and Biology</i> , 1999 , 457, 383-9	3.6	7
130	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. <i>Cancers</i> , 2020 , 12,	6.6	6
129	Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1065947	1.2	6
128	Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. <i>PLoS ONE</i> , 2008 , 3, e2144	3.7	6
127	Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1991 , 27, 397-400	3.5	6
126	Improved high-performance liquid chromatographic method using loop-column extraction for analysis of idarubicin and idarubicinol in plasma. <i>Biomedical Applications</i> , 1989 , 491, 501-6		6
125	Lipoprotein analysis in the evaluation of chest pain in the emergency department. <i>Mayo Clinic Proceedings</i> , 1991 , 66, 885-91	6.4	6
124	Anticancer therapy as a pediatric pharmacodynamic paradigm. <i>Developmental Pharmacology and Therapeutics</i> , 1989 , 13, 85-95		6
123	Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6600-6615	15.9	6
122	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1997 , 89, 1701-1707	2.2	6
121	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998 , 92, 411-415	2.2	6
120	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 361-374	3.5	6
119	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021 ,	15.9	6
118	Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients. <i>Clinical and Translational Science</i> , 2021 , 14, 964-975	4.9	6
117	Mathematical modeling of folate metabolism. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2013 , 5, 603-13	6.6	5
116	Synthesis of potential antifilarial agents 2 . methyl 2-substituted purine 8-carbamates and related compounds. <i>Journal of Heterocyclic Chemistry</i> , 1989 , 26, 1053-1059	1.9	5

115	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 618-618	2.2	5
114	Multiplex Assessment of Protein Variant Abundance by Massively Parallel Sequencing		5
113	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 933-937	9.7	5
112	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. <i>PLoS ONE</i> , 2019 , 14, e0216328	3.7	4
111	Expression arrays illuminate a way forward for mantle cell lymphoma. <i>Cancer Cell</i> , 2003 , 3, 100-2	24.3	4
110	Resequencing the sulfotransferase SUL1 gene provides new insights, while illuminating challenges that lie ahead for pharmacogenomics. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 745-6		4
109	VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2010 , 116, 273-273	2.2	4
108	Pharmacodynamic monitoring of cancer chemotherapy: childhood acute lymphoblastic leukemia as a model. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 453-8	3.2	4
107	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 794-802	6.1	4
106	Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic. <i>Advances in Experimental Medicine and Biology</i> , 1999 , 457, 537-41	3.6	4
105	A p53-regulated apoptotic gene signature predicts treatment response and outcome in pediatric acute lymphoblastic leukemia. <i>Cancer Management and Research</i> , 2017 , 9, 397-410	3.6	3
104	Synthesis of modified thiopurine nucleosides for structural characterization of human thiopurine S-methyltransferase. <i>Nucleosides & Nucleotides</i> , 1999 , 18, 1747-8		3
103	High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Children's Oncology Group (COG) Study (AALL03N1). <i>Blood</i> , 2013 , 122, 59-59	2.2	3
102	6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1. <i>Blood</i> , 2015 , 126, 82-82	2.2	3
101	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. <i>Blood</i> , 1999 , 93, 1643-1650	2.2	3
100	A journey from pediatric pharmacokinetics to pharmacogenomics. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2005 , 10, 8-13	1.6	3
99	Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia		3
98	Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2020 , 9, 6550-6555	4.8	3

97	Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. <i>Clinical and Translational Science</i> , 2021 , 14, 1490-1504	4.9	3
96	High-dose methotrexate: the rationale. <i>Journal of Pediatric Hematology/Oncology</i> , 2009 , 31, 224-5	1.2	2
95	Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 130-1		2
94	Advances in pediatric pharmacokinetics and therapeutics. <i>Journal of Pediatrics</i> , 1990 , 117, 996-1001	3.6	2
93	Modulation of the Glycolysis Pathway Reverses Prednisolone Resistance in Pediatric Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , 2008 , 112, 17-17	2.2	2
92	ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression. <i>Blood</i> , 2014 , 124, 791-791	2.2	2
91	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. <i>Blood</i> , 2015 , 126, 3714-3714	2.2	2
90	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Children's Oncology Group (COG) study AALL03N1.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10013-10013	2.2	2
89	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019 , 134, 649-649	2.2	2
88	PHASE II EVALUATION OF CISPLATIN IN CHILDREN WITH NEUROBLASTOMA AND OTHER MALIGNANT SOLID TUMORS 1980 , 477-484		2
87	Msh2 deficiency leads to dysmyelination of the corpus callosum, impaired locomotion, and altered sensory function in mice. <i>Scientific Reports</i> , 2016 , 6, 30757	4.9	2
86	Targeted Systemic Exposure for Pediatric Cancer Therapy 1991 , 177-183		2
85	Integrated Analysis of Pharmacokinetic, Clinical, and SNP Microarray Data Using Projection onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing 2009 ,		1
84	Culture trumps strategy: we must encourage the next generation of pharmacists to keep looking over the horizon and not be limited by what they can see today. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012 , 52, 450-3	1.7	1
83	Continue to study childhood ALL. <i>Blood</i> , 2008 , 111, 468-9; author reply 469	2.2	1
82	An interview with a distinguished pharmaceutical scientist. William E. Evans. <i>Pharmaceutical Research</i> , 1999 , 16, 785-9	4.5	1
81	Double-blind evaluation of 5- β final filtration to reduce postinfusion phlebitis. <i>American Journal of Health-System Pharmacy</i> , 1976 , 33, 1160-1163	2.2	1
80	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. <i>Blood</i> , 2018 , 132, 2697-2697	2.2	1

79	Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Determinants of Osteonecrosis In Children with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2010 , 116, 1033-1033	2.2	1
78	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. <i>Blood</i> , 2012 , 120, 2466-2466	2.2	1
77	Prednisolone Resistance in Pediatric Acute Lymphoblastic Leukemia Can Be Synergistically Overcome by Inhibition of Anti-Apoptotic MCL1 and Glycolysis. <i>Blood</i> , 2012 , 120, 3528-3528	2.2	1
76	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 60-60	2.2	1
75	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. <i>Blood</i> , 2014 , 124, 367-367	2.2	1
74	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 693-693	2.2	1
73	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. <i>Blood</i> , 2016 , 128, 1085-1085	2.2	1
72	Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations391-413		1
71	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 3406-3406	2.2	1
70	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 565-565	2.2	1
69	Antileukemic Efficacy of Continuous Vs Discontinuous Dexamethasone in Murine Xenografts of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014 , 124, 3701-3701	2.2	1
68	High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 1421-1421	2.2	1
67	Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 692-692	2.2	1
66	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 530-530	2.2	1
65	Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. <i>Leukemia</i> , 2021 , 35, 3078-3091	10.7	1
64	Improving the treatment of childhood acute lymphoblastic leukemia by optimizing the use of 70-year-old drugs. <i>Haematologica</i> , 2021 , 106, 2794-2796	6.6	1
63	Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1. <i>Cancer</i> , 2021 , 127, 3832-3839	6.4	1
62	Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1538-1545	6.1	1

61	Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. <i>Pharmacogenetics and Genomics</i> , 2021 ,	1.9	1
60	Concordance between Self-reported Symptoms and Clinically Ascertained Peripheral Neuropathy among Childhood Cancer Survivors: the St. Jude Lifetime Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 2256-2267	4	1
59	New insights into methotrexate accumulation in leukemia cells. <i>Molecular and Cellular Oncology</i> , 2021 , 8, 1865086	1.2	1
58	Gene expression microarrays as a prognostic test. <i>Clinical Advances in Hematology and Oncology</i> , 2005 , 3, 902-4	0.6	1
57	Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia.. <i>Science Advances</i> , 2022 , 8, eabj1360	14.3	1
56	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.. <i>Nature Genetics</i> , 2022 , 54, 170-179	36.3	0
55	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>Blood</i> , 2014 , 124, 132-132	2.2	0
54	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008 , 112, 14-14	2.2	0
53	Chemotherapy in the Pediatric Patient 2009 , 173-207		0
52	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Blood</i> , 2012 , 120, 877-877	2.2	0
51	Pharmacogenomics and Hematologic Diseases 2018 , 79-91		
50	Reply to B.A. Kamen et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3494-3495	2.2	
49	Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations309-331		
48	John H. Rodman, Pharm.D., FCCP: January 6, 1946-April 29, 2006. <i>Pharmacotherapy</i> , 2007 , 27, 1-2	5.8	
47	Pharmacodynamics of cancer chemotherapy: childhood ALL as a model. <i>International Congress Series</i> , 2001 , 1220, 203-222		
46	Academic research fellowships in clinical pharmacy. <i>Drug Intelligence & Clinical Pharmacy</i> , 1987 , 21, 106-9		
45	ACCP Forms Specialty Committee. <i>American Journal of Health-System Pharmacy</i> , 1982 , 39, 44-46	2.2	
44	Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole. <i>Drug Intelligence & Clinical Pharmacy</i> , 1975 , 9, 660-662		

- 43 Chloral Hydrate-Warfarin Interaction. *American Journal of Health-System Pharmacy*, **1975**, 32, 241-243 2.2
- 42 Unit dose radiopharmaceutical service as a component of total pharmacy practice. *American Journal of Health-System Pharmacy*, **1976**, 33, 61-63 2.2
- 41 Microbiological Hazards of Infusion Therapy. *American Journal of Health-System Pharmacy*, **1977**, 34, 775-775 2.2
- 40 Treatment of the Totally Occluded Abdominal Aorta. *Vascular Surgery*, **1978**, 12, 287-293
- 39 Comparison of Antibiotic Serum Concentrations After Intramuscular Oxacillin and Oral Cloxacillin in Children. *American Journal of Health-System Pharmacy*, **1978**, 35, 1380-1382 2.2
- 38 The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 3476-3476 2.2
- 37 Genetic Polymorphisms in the Promoter Region of the beta-2 Adrenergic Receptor Are Associated with the Early Response of Acute Lymphoblastic Leukemia to Chemotherapy.. *Blood*, **2004**, 104, 1959-1959^{2,3}
- 36 Global Gene Expression in Leukemic Blasts as a Function of Germline Genetic Variation.. *Blood*, **2004**, 104, 144-144 2.2
- 35 Genetic Polymorphisms and the Toxicity of Antileukemic Agents in Children with Acute Lymphoblastic Leukemia.. *Blood*, **2004**, 104, 1964-1964 2.2
- 34 Haplotype Structure and Pharmacogenomics. *Drugs and the Pharmaceutical Sciences*, **2005**, 441-459
- 33 Genes Regulating B-Cell Development and Differentiation Are Mutated in 40% of Pediatric Acute Lymphoblastic Leukemia.. *Blood*, **2006**, 108, 217-217 2.2
- 32 Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype. *Blood*, **2007**, 110, 2227-2227 2.2
- 31 The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 2665-2665 2.2
- 30 Clinical Pharmacodynamics of Anticancer Drugs **2019**, 389-414
- 29 Pharmacogenomics **2019**, 339-352
- 28 Clinical pharmacology of anticancer drugs in children: differences and similarities between children and adults **1987**, 29-71
- 27 Drug Concentration Monitoring. *Progress in Clinical Biochemistry and Medicine*, **1988**, 1-16
- 26 Targeted Drug Therapy in Childhood Acute Lymphoblastic Leukemia. *Hamatologie Und Bluttransfusion*, **1996**, 62-66

25	A Murine Model of Asparaginase Allergy. <i>Blood</i> , 2014 , 124, 2295-2295	2.2
24	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014 , 124, 63-63	2.2
23	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014 , 124, 3722-3722	2.2
22	Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Children's Oncology Group (COG) Study (AALL03N1). <i>Blood</i> , 2014 , 124, 369-369	2.2
21	Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 1299-1299	2.2
20	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 695-695	2.2
19	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 179-179	2.2
18	Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10514-10514	2.2
17	A Whole Genome Analysis Identifies SLCO1B1 as a Determinant of Methotrexate Pharmacokinetics and Adverse Effects. <i>Blood</i> , 2008 , 112, 214-214	2.2
16	Pharmacogenomics of childhood acute lymphoblastic leukemia (ALL). <i>Journal of Clinical Oncology</i> , 2009 , 27, s3-s3	2.2
15	Genetic Variations in GRIA1 On Chromosome 5q33 Related to Asparaginase Hypersensitivity in Childhood Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2009 , 114, 112-112	2.2
14	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2010 , 116, 8-8	2.2
13	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010 , 116, 498-498	2.2
12	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. <i>Blood</i> , 2010 , 116, 495-495	2.2
11	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. <i>Blood</i> , 2011 , 118, 571-571	2.2
10	Systemic Exposure to Dexamethasone and Asparaginase Affects Risk of Relapse in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011 , 118, 2550-2550	2.2
9	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011 , 118, 68-68	2.2
8	Aurora Kinases in Childhood Acute Leukemia: The Promise of Aurora Kinase B As Drugable Target. <i>Blood</i> , 2011 , 118, 1476-1476	2.2

7	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 878-878	2.2
6	The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia. <i>Blood</i> , 2012 , 120, 1465-1465	2.2
5	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. <i>Blood</i> , 2012 , 120, 3560-3560	2.2
4	Leukemia Cells with a BCR-ABL1-Like signature and/or IKZF1 deletions, but Not High CRLF2 Expression, Are Predictive of an Unfavorable Prognosis in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 880-880	2.2
3	BCR-ABL1-Like Cases In Pediatric Acute Lymphoblastic Leukemia: A Comparison Between COG/St. Jude and Dutch DCOG Signatures. <i>Blood</i> , 2013 , 122, 2633-2633	2.2
2	Creating an infrastructure for pediatric oncology drug development. <i>Clinical Advances in Hematology and Oncology</i> , 2007 , 5, 198-200	0.6
1	orter: A Novel Inducible Human CASP1/NALP3/ASC Inflammasome Biosensor.. <i>Journal of Inflammation Research</i> , 2022 , 15, 1183-1194	4.8